Evidence map›Paper›PMID 31324247›Full record

SynthesisBMC complementary and alternative medicine2019

Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial.

Yunfei Cai, Qiuer Liang, Weihao Chen, Minghao Chen, Ruixue Chen, Yun Zhang, Ya Xiao, Liguo Chen

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC complementary and alternative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yunfei CaiSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
Qiuer LiangSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
Weihao ChenSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
Minghao ChenDivision of Histology and Embryology, Key Laboratory for Regenerative Medicine of the Ministry of Education, Medical College, Jinan University, Guangzhou, China.
Ruixue ChenSecond Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Yun ZhangSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
Ya XiaoSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, China. xiaoya0527@126.com.
Liguo ChenSchool of Traditional Chinese Medicine, Jinan University, Guangzhou, China. tchenly@jnu.edu.cn.

Funding

the Administration of Traditional Medicine of Guangdong province No. 20161063 and No. 20181068the Fundamental Research Funds for the Central Universities No. 21616315the Medical Scientific Research Foundation of Guangdong Province No. 2016111221315850the National Natural Sciences Foundation of China No. 81673848 and 81603520the Natural Sciences Foundation of Guangdong province No. 2016A030310084 and 2017A030313658the Science & Technical Plan of Guangzhou, Guangdong, China No. 201707010100 and NO.201804010213
6 · The paper itself

Abstract

backgroundTo evaluate the effectiveness and safety of HuoXueHuaYu (HXHY) therapy in treating nonalcoholic fatty liver disease (NAFLD) through a systematic review and meta-analysis.

methodsWe performed comprehensive searches on Embase, Pubmed, Cochrane Library, CNKI, VIP and Wanfang databases up to June 2017 for randomized controlled trials using HXHY in the treatment of NAFLD compared with conventional treatment.

resultsThis meta-analysis included 13 studies involving 1429 patients which 775 patients belonged to HXHY group and 654 patients belonged to conventional treatment group. The results of meta-analysis showed that HXHY can significantly improve B ultrasonic level (OR = 2.33; 95% CI:1.60, 3.40; P < 0.00001) of NAFLD compared with conventional treatment. As to lipids, HXHY was tested to be better on reduction of total cholesterol (TC) (MD = -0.38, 95% CI: - 0.48, - 0.29; P < 0.00001) and triglyceride (TG) (MD = -0.31; 95% CI: - 0.37, - 0.24; P < 0.00001) than conventional treatment. HXHY also had a greater beneficial effect on liver function in reducing alanine transaminase (ALT) (MD = -1.69; 95% CI: - 2.24, - 1.14; P < 0.00001) and aspartate transaminase (AST) (MD = -22.53; 95% CI: - 33.16, - 11.90; P < 0.00001) compared with conventional treatment. HXHY can also significantly improve the effective rate (OR = 3.55; 95% CI:2.65, 4.76; P < 0.00001) compared with conventional treatment. No serious adverse reactions were reported.

conclusionsHXHY seems to be an effective and safe therapy for NAFLD. It is suggested that further study of HXHY in the treatment of NAFLD requires trials with rigorous design, multicenter, large-scale and high-quality worldwide.

Indexed as

AdultAgedDrugs, Chinese HerbalFemaleHumansLiverMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseRandomized Controlled Trials as TopicTreatment OutcomeTriglyceridesDrugs, Chinese HerbalTriglyceridesHuoxuehuayuMeta-analysisNAFLD

Identifiers

PMID31324247
PMCPMC6642602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.